Evidence map›Paper›PMID 35369017›Full record

ArticleKidney3602021

Machine Learning for Prediction of Patients on Hemodialysis with an Undetected SARS-CoV-2 Infection.

Caitlin K Monaghan, John W Larkin, Sheetal Chaudhuri, Hao Han, Yue Jiao, Kristine M Bermudez, Eric D Weinhandl, Ines A Dahne-Steuber, Kathleen Belmonte, Luca Neri and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Kidney360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Detection of COVID-19 Patients Using Machine Learning Techniques: A Nationwide Chilean Study.International journal of environmental research and public health · 2022
    Article
  10. Article
  11. Article
  12. Trajectories of clinical and laboratory characteristics associated with COVID-19 in hemodialysis patients by survival.Hemodialysis international. International Symposium on Home Hemodialysis · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Caitlin K MonaghanFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.
John W LarkinFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.ORCID 0000-0001-8873-8971
Sheetal ChaudhuriFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.
Hao HanFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.
Yue JiaoFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.
Kristine M BermudezFresenius Medical Care North America, Medical Office, Waltham, Massachusetts.
Eric D WeinhandlFresenius Medical Care North America, Medical Office, Waltham, Massachusetts.
Ines A Dahne-SteuberFresenius Medical Care North America, Medical Office, Waltham, Massachusetts.
Kathleen BelmonteNursing & Clinical Services, Fresenius Kidney Care, Waltham, Massachusetts.
Luca NeriFresenius Medical Care Deutschland GmbH, EMEA Medical Office, Bad Homburg, Germany.
Peter KotankoResearch Division, Renal Research Institute, New York, New York.
Jeroen P KoomanDivision of Nephrology, Maastricht University Medical Center, Maastricht, The Netherlands.
Jeffrey L HymesFresenius Medical Care North America, Medical Office, Waltham, Massachusetts.
Robert J KossmannFresenius Medical Care North America, Medical Office, Waltham, Massachusetts.
Len A UsvyatFresenius Medical Care, Global Medical Office, Waltham, Massachusetts.
Franklin W MadduxFresenius Medical Care AG & Co. KGaA, Global Medical Office, Bad Homburg, Germany.
Fresenius Medical Care (United States) · USFresenius Medical Care (Germany) · DEMaastricht University · NLRenal Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We developed a machine learning (ML) model that predicts the risk of a patient on hemodialysis (HD) having an undetected SARS-CoV-2 infection that is identified after the following ≥3 days. Methods: As part of a healthcare operations effort, we used patient data from a national network of dialysis clinics (February-September 2020) to develop an ML model (XGBoost) that uses 81 variables to predict the likelihood of an adult patient on HD having an undetected SARS-CoV-2 infection that is identified in the subsequent ≥3 days. We used a 60%:20%:20% randomized split of COVID-19-positive samples for the training, validation, and testing datasets. Results: We used a select cohort of 40,490 patients on HD to build the ML model (11,166 patients who were COVID-19 positive and 29,324 patients who were unaffected controls). The prevalence of COVID-19 in the cohort (28% COVID-19 positive) was by design higher than the HD population. The prevalence of COVID-19 was set to 10% in the testing dataset to estimate the prevalence observed in the national HD population. The threshold for classifying observations as positive or negative was set at 0.80 to minimize false positives. Precision for the model was 0.52, the recall was 0.07, and the lift was 5.3 in the testing dataset. Area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) for the model was 0.68 and 0.24 in the testing dataset, respectively. Top predictors of a patient on HD having a SARS-CoV-2 infection were the change in interdialytic weight gain from the previous month, mean pre-HD body temperature in the prior week, and the change in post-HD heart rate from the previous month. Conclusions: The developed ML model appears suitable for predicting patients on HD at risk of having COVID-19 at least 3 days before there would be a clinical suspicion of the disease.

Indexed as

COVID-19AdultHumansMachine LearningRenal DialysisROC CurveSARS-CoV-2artificial intelligencecoronavirusCOVID-19dialysisend stage kidney diseasemachine learningpredictionSARS-CoV-2

Identifiers

PMID35369017
PMCPMC8786002
OpenAlexW3119052010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.